The assets of DermaSilk manufacturer Biotech International Corporation have been put up for sale by asset valuations company Tiger Group.
DermaSilk is a leading anti-aging skin care brand in North America and features 13 different SKUs, including Miracle Cream, Double Chin Firming, 5 Minute Beauty Peel and 1 Minute Collagen Lift.
The line is recognized as being in the top ten anti-aging products in the US, and is sold in major retailers such as CVS, Walgreens and Wal-Mart, as well as a selection of dedicated online retailers.
A top ten anti-aging brand in the US
“Health and beauty companies, or other businesses with skincare and cosmetic lines will be interested in this unique opportunity for a brand that ranked sixth domestically in a category that includes such names as Oil of Olay, L’Oreal and Neutrogena,” said Andy Babcock, Tiger Group’s Director of Inventory Strategies.
“Demand for DermaSilk continues to be robust,” he said, ahead of the bidding process, which is due to close next week.
Tiger Group is acting on behalf of the First Niagara Bank, which is the secured creditor for Biotech International as the broker for the sale and is requesting that sealed bids should be received no later than 5pm EST, February 19th.
Bids for turnkey business or specific assets close February 19th
The company said it is accepting offers for the business on a turnkey basis, or in any combination of individual product lines or associations to the business units of packaging and displays and an estimated $1 million of finished goods.
Assets in the sale will include all of the popular product lines and trademarks for DermaSilk, its trademarked formulations and ongoing customer lists.
The DermaSilk brand targets the $2.1 billion global anti-aging market, the fastest growing segment of an overall skin care market that is currently valued in excess of $90 billion.